As the six approved CAR-T cell therapies, including Breyanzi®, Abecma™ and CARVYKTI™ are poised to achieve blockbuster status, along with a promising development pipeline, the field of CAR-T cell therapies has gained significant traction

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035.”

The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:

§  A detailed assessment of the current market landscape of CAR-T-cell therapies.

§  An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors.

§  A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies.

§  An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies.

§  Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above).

§  An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies.

§  An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies.

§  An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022.

§  A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.

§  An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.

§  A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies.

§  Elaborate profiles of the several leading players in the domain of CAR-T cell therapies.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):

§  Target Indication(s)

§  Non-Hodgkin’s Lymphoma

§  Multiple Myeloma

§  Acute Lymphoblastic Leukemia

§  Chronic Lymphocytic Leukemia

§  Hodgkin’s Lymphoma

§  Acute Myeloid Leukemia

§  Ovarian Cancer

§  Generalized Myasthenia Gravis (MG)

§  Renal Cell Carcinoma

§  Target Antigen

§  CD19

§  BCMA

§  CD19/22

§  Others

§  Key Geographical Regions 

§  North America

§  Europe

§  Asia Pacific

§  Latin America

§  Middle East and North Africa

§  Rest of the World 

Transcripts of interviews held with the following senior level representatives of stakeholder companies:

§  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)

§  Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)

§  Miguel Forte (Chief Operating Officer, TxCell)

§  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)

§  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)

§  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

§  Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)

§  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)

§  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players. 

§  Autolus

§  bluebird Bio

§  Bristol Myers Squibb

§  Carsgen Therapeutics

§  Cellectis

§  Cellular Biomedicine Group

§  Gilead Sciences

§  Innovative Cellular Therapeutics

§  Kuur Therapeutics

§  Noile-Immune Biotech

§  Novartis

§  Shanghai GeneChem

§  Sinobioway Cell Therapy

§  Takara Bio

§  Wellington Zhaotai Therapies

Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

You may also be interested in the following titles:

DNA Encoded Libraries

Quantum Computing in Drug Discovery Services Market

You may also like to learn what our experts are sharing in Roots educational series:

mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule

TIL Therapies: A New Paradigm in Cancer Treatment

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

[email protected]